Microbiome Diagnostics Market Size is valued at USD 154.9 Mn in 2023 and is predicted to reach USD 488.2 Mn by the year 2031 at a 15.6% CAGR during the forecast period for 2024-2031.
Utilizing advanced genomic and bioinformatic techniques, these diagnostics can profile microbial DNA from samples (e.g., gut, skin, oral cavity) to understand the composition and function of the microbiome. Applications range from disease diagnosis and risk assessment to personalized medicine and predicting drug responses, by identifying specific microbiome signatures associated with certain diseases or health states.
The Microbiome Diagnostics market growth can be attributed to its use of progressive scientific procedures and technologies to inspect the configuration and operation of microbiomes in particular environments, especially within the human body. The microbiome diagnostics market is witnessing steady growth, driven by increasing awareness of the role of microbial communities in health and disease. Advancements in technologies and bioinformatics have enabled more accurate and comprehensive microbiome analysis. However, challenges such as standardization of testing protocols and regulatory hurdles remain, shaping the landscape of this rapidly evolving Market.
The COVID-19 pandemic has positively as well as negatively impacted the microbiome diagnostics market. While there has been increased interest in understanding the pivotal role of the microbiome in immunity and disease susceptibility, disruptions in healthcare systems and reduced research funding have slowed market growth. However, the pandemic has increased the adoption of remote healthcare solutions, leading to a surge in demand for microbiome diagnostics for telemedicine and home testing. Overall, the Market has faced challenges regarding supply chain disruptions and reduced access to healthcare facilities. Still, opportunities have emerged in remote diagnostics and personalized medicine.
Competitive Landscape
Some Major Key Players In The Microbiome Diagnostics Market:
- Yakult Honsha Co.
- AOBiome
- Enterome Biosciences SA
- Metabiomics Corp. (BioSpherex LLC)
- Microbiome Therapeutics LLC
- Osel, Inc.
- Rebiotix, Inc.
- Second Genome
- Seres Therapeutics
- Synthetic Biologics, Inc.
- Vedanta Biosciences
- 4D Pharma
- Du Pont De Nemours and Co.
- Ferring Pharmaceuticals
- Genetic Analysis AS
- Atlas Biomed
- Biome Oxford Ltd.
- Illumina Inc.
- Microba Life Sciences
- Dna Genotek (Orasure Technologies, Inc.)
- Viome Life Sciences
- Sun Genomics
- Becton, Dickinson And Company
- Daytwo
- OraSure Technologies, Inc.
- Other Prominent Players
Market Segmentation:
The Microbiome Diagnostics Market is segmented by product, Technology, sample, application, end-user, and region. The segmentation based on the products is Reagents & Kits and Instruments. The sample segment comprises Fecal, Saliva, and Skin. Based on application, the segmentation includes Disease Diagnostics Applications, Gastrointestinal Disorders, Metabolic Diseases, and Other Applications. Based on End-User, the segmentation includes Hospitals, Academic and Research Institutes, Biotechnology, and Pharmaceutical Companies.
The Kits & Reagents Accounted For The Largest Share Of The Microbiome Diagnostics Market By Product Segment.
High consumption of consumables such as kits and reagents and their repeated purchases, along with the increasing number of microbiome diagnostic tests performed across the globe, support the growth of the reagents & kits product segment. The demand for microbiome diagnostics is rising as the instruments play an important role in sanctioning the correct and precise investigation of microbiome samples. Next-generation sequencing apparatus, mass spectrometers, and quantitative PCR gadgets are important in this field. NGS devices are important for sequencing DNA and RNA from microbiome samples, offering comprehensive particulars about the configuration of microbial sections.
The Pharmaceutical And Biotechnologies Segment Based On End-Users Has Also Witnessed Rapid Growth.
The Pharmaceutical and Biotechnologies Segment dominated the Market based on end users. They appear as a sizeable fragment of microbiome diagnostics end users. The microbiome diagnostics market trends include utilizing microbiome data to fabricate inventive remedies, customized medicines, and progressive probiotics. These firms are entrenched in disentangling the complex associations between the human microbiome and varied illnesses. By engaging microbiome diagnostics, they project to distinguish contemporary drug targets, enhance drug efficacy, and lessen the prevalence of unfavourable outcomes.
North America Is The Region That Has A Significant Revenue Share In The Microbiome Diagnostics Market.
North America emerges as the most dominant Market due to the region's strong healthcare framework, the notable pervasiveness of gastrointestinal illnesses, and growing consciousness regarding the importance of microbiome balance, which are important elements pushing the assimilation of microbiome diagnostics within the region. North America dominates the microbiome market because of the strong base of healthcare facilities, rising investment from key players, a growing number of processes about drug development, and a rising number of research activities in this region. The joint ventures regarding research between leading economies of this region also boost the market growth. There is an increase in government initiatives to promote awareness, growing research and education activities in the region, a rise in the incidences of lifestyle-related diseases and autoimmune disorders, and a growing demand for quality healthcare.
Recent Developments
- In July 2022, OraSure Technologies, Inc. has made its OMNIgene®•GUT DNA and RNA product (OMR-205) available to researchers studying the gut microbiota. OraSure technology is a prominent worldwide frontrunner in the field of point-of-care and home diagnostic testing, as well as sample collecting technology. The product facilitated the collection, preservation, storage, and transfer of microbial DNA and RNA at room temperature for the purpose of analyzing the gut microbiome. The product was manufactured by DNA Genotek, a subsidiary of OraSure.
- In Aug 2021, A partnership between Second Genome and Arena Pharmaceuticals to identify gastrointestinal biomarkers was recently disclosed. A proof-of-concept study utilizing microbiome signals was conducted by Second Genome as part of Arena's CULTIVATE Phase 2/3 clinical trial for Crohn's disease.
Microbiome Diagnostics Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 154.9 Mn |
|
Revenue Forecast In 2031 |
USD 488.2 Mn |
|
Growth Rate CAGR |
CAGR of 15.6 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, Technology, Sample, Application, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Yakult Honsha Co., AOBiome, Enterome Biosciences SA, Metabiomics Corp., Microbiome Therapeutics LLC, Osel, Inc., Rebiotix, Inc., Second Genome, Seres Therapeutics, Synthetic Biologics, Vedanta Biosciences, 4D Pharma, Du Pont De Nemours and Co., Ferring Pharmaceuticals, Genetic Analysis AS, Atlas Biomed, Biome Oxford Ltd., Illumina Inc., Microba Life Sciences, Dna Genotek (Orasure Technologies, Inc.), Viome Life Sciences, Sun Genomics, Becton, Dickinson And Company, Daytwo, OraSure Technologies, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
